Bentley’s entrepreneurial team has positioned us as the European market leader in covered stents enabling minimal invasive interventions substituting open surgery. We are propelled by the megatrend of an aging population that increasingly requires endovascular treatment of aortic and peripheral diseases. Continuously challenging ourselves, we are always striving to exceed our customers’ expectations (whilst matching our own) by offering cutting-edge products and services enabling physicians to improve quality of life of patients suffering from vascular diseases.

We are dedicated to fast, but healthy growth, which is driven by our highly committed, excellently skilled employees. This is reflected in our constantly rising market presence and sales volumes – and in our financial performance.

At Bentley, we are committed to deliver added value for all our stakeholders: for the patients treated with our endovascular solutions, for our employees passionate about supplying top-notch quality and for our shareholders. The recent engagement of Keensight Capital A.P. Møller Holding and Bonit Capital as new shareholders is a proof of the high esteem of the financial community for our innovation-driven business and our performance. The continued strong position of the founders and management will secure our position as an independent player. The stage is set. I firmly believe that our success will continue for many years to come.

Sebastian Büchert, CEO